Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy

Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Ali, Robert, Arshad, Junaid, Palacio, Sofia, Mudad, Raja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372006/
https://www.ncbi.nlm.nih.gov/pubmed/30804663
http://dx.doi.org/10.2147/DDDT.S147499
_version_ 1783394671611871232
author Ali, Robert
Arshad, Junaid
Palacio, Sofia
Mudad, Raja
author_facet Ali, Robert
Arshad, Junaid
Palacio, Sofia
Mudad, Raja
author_sort Ali, Robert
collection PubMed
description Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC.
format Online
Article
Text
id pubmed-6372006
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-63720062019-02-25 Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy Ali, Robert Arshad, Junaid Palacio, Sofia Mudad, Raja Drug Des Devel Ther Review Despite the benefits of first and second generation anaplastic lymphoma kinase (ALK) inhibitors in the management of ALK-rearranged advanced non-small-cell lung cancer (NSCLC), the development of acquired resistance poses an ongoing dilemma. Brigatinib has demonstrated a wider spectrum of preclinical activity against crizotinib-resistant ALK mutant advanced NSCLC. The current review narrates a brief history of tyrosine kinases, the development and clinical background of brigatinib (including its pharmacology and molecular structure) and its use in ALK-positive NSCLC. Dove Medical Press 2019-02-08 /pmc/articles/PMC6372006/ /pubmed/30804663 http://dx.doi.org/10.2147/DDDT.S147499 Text en © 2019 Ali et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Ali, Robert
Arshad, Junaid
Palacio, Sofia
Mudad, Raja
Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
title Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
title_full Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
title_fullStr Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
title_full_unstemmed Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
title_short Brigatinib for ALK-positive metastatic non-small-cell lung cancer: design, development and place in therapy
title_sort brigatinib for alk-positive metastatic non-small-cell lung cancer: design, development and place in therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372006/
https://www.ncbi.nlm.nih.gov/pubmed/30804663
http://dx.doi.org/10.2147/DDDT.S147499
work_keys_str_mv AT alirobert brigatinibforalkpositivemetastaticnonsmallcelllungcancerdesigndevelopmentandplaceintherapy
AT arshadjunaid brigatinibforalkpositivemetastaticnonsmallcelllungcancerdesigndevelopmentandplaceintherapy
AT palaciosofia brigatinibforalkpositivemetastaticnonsmallcelllungcancerdesigndevelopmentandplaceintherapy
AT mudadraja brigatinibforalkpositivemetastaticnonsmallcelllungcancerdesigndevelopmentandplaceintherapy

Ejemplares similares